VIMALA RAVI: Open Payments
NPI 1811437296 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$945 in 48 payments from 10 companies in 2025. Trend: 2023 $910 · 2024 $1,899 · 2025 $945
Food & beverage: $945
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $268 |
| Novo Nordisk Inc | 9 | $185 |
| Lilly USA, LLC | 13 | $155 |
| AstraZeneca Pharmaceuticals LP | 5 | $104 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $101 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Astellas Pharma US Inc | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| SHIELD THERAPEUTICS INC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
Products named: Kerendia, JARDIANCE, FARXIGA, Ozempic, MOUNJARO, Wegovy, NEXLETOL, KISUNLA.
Industry payments across TX — which companies pay providers there.
